ArticleDiabetes, obesity & metabolism2026
Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Gout Risk: A Population-Based Comparative Cohort Study With Genetic Evidence From Mendelian Randomisation.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimSodium-glucose cotransporter-2 inhibitors (SGLT2i) are known to reduce serum urate levels, yet their specific impact on gout incidence in the Korean population remains underexplored. We investigated the association between SGLT2i use and incident gout using real-world data and Mendelian randomisation (MR) analysis. MATERIALS AND
methodsWe conducted a population-based cohort study using the Korean National Health Insurance Service database (2015-2020). New users of SGLT2i were compared to dipeptidyl peptidase-4 inhibitor (DPP4i) users. After 1:1 propensity score matching (PSM), 20 866 pairs were analysed using Cox proportional hazards models. The primary outcome was incident gout. Additionally, a two-sample MR analysis utilised genetic variants in SLC5A2 as proxies for SGLT2 inhibition and gout summary statistics from the FinnGen consortium.
resultsIn the cohort study, SGLT2i use was associated with a significantly lower risk of gout compared to DPP4i (incidence rate: 2792.6 vs. 3346.7 per 100 000 person-years). The hazard ratio in the PSM model was 0.80 (95% confidence interval [CI] 0.76-0.84, p value < 0.001). This finding was robust across multiple sensitivity analyses, including landmark and time-varying exposure models. In the MR analysis, genetically proxied SGLT2 inhibition was associated with a reduced risk of gout (odds ratio 0.10 per 1-standard deviation decrease in HbA1c; 95% CI: 0.017-0.463; p value < 0.001), with consistent results across robust MR methods.
conclusionSGLT2i therapy is associated with a lower risk of incident gout compared to DPP4i in patients with type 2 diabetes. While these findings suggest potential pleiotropic effects of SGLT2i beyond glucose control, they should be interpreted with caution given the limitations of observational study designs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.